Acrosoxacin in the treatment of uncomplicated gonorrhoea.
Acrosoxacin was given as a single 300 mg oral dose to 105 patients with acute gonorrhoea. Of the 100 patients followed completely there was a 93% cure rate and 33% of men developed postgonococcal urethritis (PGU). This compared with a 97% cure and 30% PGU with 2 megaunits penicillin. The in vitro activity of acrosoxacin in Nottingham against strains of Neisseria gonorrhoeae showed that it was a highly active agent with 90% of strains inhibited by a concentration of 0.03 mg/l.
D042462:4-Quinolones; D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D010406:Penicillins / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D010406:Penicillins; D011804:Quinolines; D015363:Quinolones; C021083:rosoxacin